DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis



Status:Completed
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 90
Updated:4/21/2016
Start Date:January 2014
End Date:October 2014

Use our guide to learn which trials are right for you!

The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA
(hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily
for 15 days.


Inclusion Criteria:

1. Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque
psoriasis.

2. Subjects with psoriasis involving 20 to 50% BSA, not including the face, scalp,
groin, axillae and other intertriginous areas.

3. Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit

4. Subjects whose results from the screening ACTH stimulation test are considered normal
(cortisol level >18 ug/dL at 30 minutes post stimulation) and show no other signs of
abnormal HPA function or adrenal response. -

Exclusion Criteria:

1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,
exfoliative or pustular psoriasis.

2. History of organ transplant requiring immunosuppression, HIV, or other
immunocompromised state.

3. Have received treatment for any type of cancer within 5 years of the Baseline Visit
except skin cancer and cervical cancer (in situ) are allowed if at least 1 year
before the Baseline Visit.

4. Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g.,
tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g.,
methotrexate, cyclosporine, hydroxyurea)

5. Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs
(salicylic acid, anthralin, coal tar, calcipotriene)2) PUVA therapy, 3) systemic
anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine),
or 4) UVB therapy.

6. Use within 30 days prior to the Screening Visit of any product containing
corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.

7. Subjects who have an abnormal sleep schedule or work at night.

8. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased
adrenal output, low pituitary function or pituitary tumors.

9. Subjects who have a history of an adverse reaction to cosyntropin injection or
similar test reagents.
We found this trial at
12
sites
Albuquerque, New Mexico 87106
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
7000 Fannin St
Houston, Texas 77030
(713) 500-4472
University of Texas Health Science Center at Houston The University of Texas Health Science Center...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Austin, Texas 78759
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
?
mi
from
Encino, CA
Click here to add this to my saved trials
Henderson, Nevada 89014
?
mi
from
Henderson, NV
Click here to add this to my saved trials
High Point, North Carolina 27262
?
mi
from
High Point, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Katy, TX
Click here to add this to my saved trials
Nashville, Tennessee 37215
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19103
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Santa Rosa, California 95403
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials